Targeted delivery of gene-editing tools to eliminate HIV from the body
Lentivirus-like particle specific delivery of Cas12 ribonucleoprotein (RNP) to HIV reservoir cells in vivo for an HIV cure
This study is exploring a new way to deliver gene-editing tools directly to HIV-infected cells, which could help remove the virus and improve treatment for people living with HIV.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virginia Commonwealth University NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project ID | NIH-11037998 on NIH RePORTER |
What this research studies
This research focuses on developing a novel method to deliver gene-editing tools specifically to cells infected with HIV. By using a specially designed lentivirus-like particle, the study aims to transport Cas12 ribonucleoprotein and mRNA directly to CD4-expressing cells, which are key targets for HIV. The approach seeks to excise HIV proviral DNA and the CCR5 co-receptor, potentially leading to a functional cure for HIV. Patients may benefit from this innovative strategy that aims to improve the precision and effectiveness of HIV treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who have not responded adequately to standard antiretroviral therapies.
Not a fit: Patients who are not infected with HIV or those who have advanced AIDS may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a functional cure for HIV, significantly improving the lives of those living with the virus.
How similar studies have performed: Previous research has shown promise in using similar gene-editing approaches for HIV treatment, indicating potential for success in this novel application.
Where this research is happening
Richmond, United States
- Virginia Commonwealth University — Richmond, United States (Active)
Researchers
- Principal investigator: Hu, Wenhui — Virginia Commonwealth University
- Study coordinator: Hu, Wenhui
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.